research Lower Prostate Cancer Risk in Swedish Men with the Androgen Receptor E213 A-Allele
Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
Search
forLearn
0 / 0 results — no results
Research
5 / 851 results 
research Identification and Molecular Characterization of a New Ovarian Cancer Susceptibility Locus at 17q21.31
A new genetic region, 17q21.31, is linked to higher ovarian cancer risk.
research Association of Estrogen Receptor Gene Variants (ESR1 and ESR2) with Polycystic Ovary Syndrome in Tunisia
Certain gene variants in estrogen receptors are linked to polycystic ovary syndrome, mainly affecting metabolism, in Tunisian women.
research Genetic Diversity and Phylogeography of the Endemic Species Prunus Mira in the Qinghai-Tibetan Plateau
Prunus mira has high genetic diversity due to geographic isolation, needing targeted conservation.
research Recent Positive Selection of a Human Androgen Receptor/Ectodysplasin A2 Receptor Haplotype and Its Relationship to Male Pattern Baldness
A specific genetic mutation may increase male pattern baldness risk, especially in Europeans.
Community Join
5 / 10 resultscommunity July 1st - Early H2 - Breezula
Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.
community What has happened to Breezula?
Breezula is expected to launch in late 2026, with data being sent to the FDA in early 2026. The process is typical for a successful trial.
community Breezula(CB)Phase3Results Date
Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.
community New Breezula Update ( I think)
Breezula's phase 3 enrollment for hair loss treatment is complete, but results have not been published, causing skepticism about its progress. Some users express doubt about its future, suggesting it may be reserved for exclusive use.
community Possibility of updates or more information on the pp405
The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.